Summary
Amgen Inc. (AMGN) filed an 8-K on April 21, 2005, to report its financial and operational results for the first quarter ended March 31, 2005. The filing includes condensed consolidated statements of operations, detailed product sales for the quarter, and condensed consolidated balance sheets. This report is also being filed in conjunction with a previously announced exchange offer where Amgen is offering to exchange new Zero Coupon Convertible Notes due 2032 for its outstanding Liquid Yield Option Notes due 2032, which is set to expire on May 4, 2005. The company is leveraging this 8-K filing to incorporate its first-quarter financial information, making it available to the SEC and investors as part of its ongoing exchange offer. Investors should review the attached exhibits for detailed financial performance and the status of the note exchange offer.
Key Highlights
- 1Amgen Inc. reported its first-quarter 2005 financial results on April 21, 2005.
- 2The filing includes unaudited condensed consolidated statements of operations for Q1 2005 and Q1 2004.
- 3Detailed product sales information for the three months ended March 31, 2005, and 2004, is provided.
- 4Condensed consolidated balance sheets as of March 31, 2005, and December 31, 2004, are included.
- 5The 8-K filing is being used to satisfy a Rule 425 communication requirement related to an ongoing exchange offer.
- 6Amgen is conducting an exchange offer for its Liquid Yield Option Notes due 2032, expiring May 4, 2005.
- 7The company is offering new Zero Coupon Convertible Notes due 2032 in exchange for the outstanding notes.